Spruce Biosciences, Inc. cash flow to debt ratio of -4.53K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Spruce Biosciences, Inc.'s free cash flow has increased -40.45% from $-55.96M last year to $-33.33M, signaling increasing performance

Spruce Biosciences, Inc.'s debt to equity ratio is 0.21, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Spruce Biosciences, Inc.'s debt has increased relative to shareholder equity from 0.10 last year to 0.21 today, signaling weakened financials

Spruce Biosciences, Inc. has negative EBITDA, making leverage ratio unreliable

Spruce Biosciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Spruce Biosciences, Inc.'s profit margin has increased (-100.00%) in the last year from -1.08K% to 0.00%, signaling increasing performance

Spruce Biosciences, Inc.'s short-term assets of $52.11M exceed its short-term liabilities of $10.09M

Spruce Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Spruce Biosciences, Inc.'s return on equity of -155.40%, is lower than 15.00%, indicating bad performance

Spruce Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Spruce Biosciences, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Spruce Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Spruce Biosciences, Inc. has negative free cash flow, indicating cash burn

Spruce Biosciences, Inc.'s yearly earnings has increased -26.53% since last year from $-53.04M to $-38.97M, signaling increasing performance

Spruce Biosciences, Inc.'s yearly revenue has decreased -100.00% since last year from $4.91M to $0.00, signaling decreasing performance

ROIC -74.40% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Spruce Biosciences, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Spruce Biosciences, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Spruce Biosciences, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Spruce Biosciences, Inc. has insufficient data to evaluate this check.

Spruce Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Spruce Biosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Spruce Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Spruce Biosciences, Inc. has insufficient data to evaluate this check.

Spruce Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Spruce Biosciences, Inc. has a price-to-book ratio of 2.18x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Spruce Biosciences, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue